CAR-T cell therapy, originally developed for cancer, is showing ever more promise as a treatment for autoimmune diseases.
Ten UCSF graduate students presented their research in accessible, 3-minute talks at the 2026 Grad Slam event. This year’s ...
Former Sen. Ben Sasse is taking Revolution Medicines' daraxonrasib, which has shown promise as a treatment for pancreatic ...
Korean pharmaceutical and biotech corporations will unveil next-generation anticancer research at the American Association for Cancer Research (AACR), to be held in San Diego from the 17th to the 22nd ...
In 1977, Richard Peto, a British epidemiologist, theorized that large-bodied animals like elephants are more likely to ...
The study investigated r ezatapopt (PC14586), a first-in-class small molecule designed to selectively bind and reactivate the ...
Fi Novelist Who Disappeared for Decades In “What We Are Seeking,” the cult author Cameron Reed returns to show us a strange, ...
LG Chem has doubled down on developing an innovative cancer treatment by zeroing in on undruggable targets through a ...
FMC-220 was discovered using the Frontier (TM) Platform, integrating chemoproteomics and AI for covalent-based drug discovery. FMC-220 is the second potential first-in-class program to advance from ...
Vietnam Investment Review on MSN
Sequencio presents cancer vaccine research at AACR meeting
HONG KONG SAR - Media OutReach Newswire - 31 March 2026 - Sequencio Therapeutics Company Limited ("Sequencio"), a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences"), today ...
Discover how TP53 mutations in adult leukaemia impact treatment outcomes and potential strategies for improved patient care.
A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results